Major changes are coming to how doctors recommend Americans think about their cholesterol levels, courtesy of a change to ...

Emerging evidence may help reshape antiplatelet and lipid strategies for the management of coronary artery disease.

A Prescription Drug User Fee Act target date of December 12, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the Biologics License Application ...

In another study of dyslipidemic patients not treated with hypolipidemic drugs (baseline examination), a very good correlation between LDL-C and apoB (r = 0.903; p < 0.001) was found. [66] In spite of ...

Compared with placebo, obicetrapib lowered LDL-C by 33% at day 84 (P .0001). Topline results were announced from a phase 3 trial evaluating obicetrapib, an investigational low dose cholesterol ester ...

In patients with cardiovascular disease or who are at high risk for CVD, lerodalcibep significantly decreases LDL-C. Lerodalcibep significantly decreases low-density lipoprotein cholesterol (LDL-C) in ...

The ACC and AHA have released new dyslipidemia guidelines focusing on earlier intervention, updated risk assessment tools, and more aggressive LDL cholesterol targets. The recommendations encourage ...

ApoB testing outperforms traditional cholesterol measures in preventing heart attacks and strokes while remaining ...

The prevalence of severely elevated low-density lipoprotein cholesterol (LDL-C) has declined in recent decades, but 1 in 17 US adults in a recent analysis had levels of LDL-C that would warrant ...

People with low levels of low-density lipoprotein cholesterol (LDL-C) in their blood have a lower risk of dementia, including lower risk of Alzheimer's disease related dementia, shows a study ...